- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging targeted agents in metastatic breast cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 10, Issue 4, Pages 191-210
Publisher
Springer Nature
Online
2013-03-05
DOI
10.1038/nrclinonc.2013.29
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.
- (2017) N. W. Peacock et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.
- (2017) H. S. Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR) –positive advanced breast carcinoma resistant to standard endocrine therapies.
- (2017) B. Basu et al. JOURNAL OF CLINICAL ONCOLOGY
- Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study.
- (2017) Tanios S. Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of peripheral blood guanylyl cyclase C (GCC) expressions with prognostic parameters and response to therapy in patients with colorectal cancer.
- (2017) Celalettin Camci et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot study of pharmacokinetically guided dose management of capecitabine in CRC patients.
- (2017) Katsuya Makihara et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells
- (2015) Oncotarget
- Tumor-Endothelial Interaction Links the CD44+/CD24- Phenotype with Poor Prognosis in Early-Stage Breast Cancer
- (2015) Martin Buess et al. NEOPLASIA
- New drug development
- (2012) R. S. Finn et al. ANNALS OF ONCOLOGY
- CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis
- (2012) Angelo Ferrari et al. BMC Veterinary Research
- Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
- (2012) Tobias J. Grob et al. BREAST CANCER RESEARCH AND TREATMENT
- Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production
- (2012) Zhi Shi et al. BREAST CANCER RESEARCH AND TREATMENT
- Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells
- (2012) Warren Fiskus et al. BREAST CANCER RESEARCH AND TREATMENT
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
- (2012) Hsing-Chen Tsai et al. CANCER CELL
- Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
- (2012) Jeffrey A. Magee et al. CANCER CELL
- P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial.
- (2012) SM Tolaney et al. CANCER RESEARCH
- Abstract LB-194: The Wnt inhibitor VS-507 reduces cancer stem cell (CSC) function in vitro and tumorigenicity in mice
- (2012) J. A. Pachter et al. CANCER RESEARCH
- Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
- (2012) D. Juric et al. CANCER RESEARCH
- Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398in vitro
- (2012) Richard S. Finn et al. CANCER RESEARCH
- CCL2 Mediates Cross-talk between Cancer Cells and Stromal Fibroblasts That Regulates Breast Cancer Stem Cells
- (2012) A. Tsuyada et al. CANCER RESEARCH
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
- (2012) A. B. Turke et al. CANCER RESEARCH
- Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway
- (2012) B. Ramaswamy et al. CANCER RESEARCH
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells
- (2012) Eleftherios Sachlos et al. CELL
- A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
- (2012) Swarnali Acharyya et al. CELL
- Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
- (2012) J. T. Garrett et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on Hedgehog Signaling
- (2012) N. B. Hassounah et al. CLINICAL CANCER RESEARCH
- Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition
- (2012) Dimitrios Zardavas et al. CURRENT OPINION IN ONCOLOGY
- Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study
- (2012) Petra dos Santos et al. Diagnostic Pathology
- Integrin bi-directional signaling across the plasma membrane
- (2012) Ping Hu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Parallel Lives Diverge
- (2012) Daniel Rayson JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
- (2012) Hope S. Rugo JOURNAL OF CLINICAL ONCOLOGY
- Screening Patients With Colorectal Cancer for Lynch Syndrome: What Are We Waiting For?
- (2012) Fay Kastrinos et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis
- (2012) Carmen Chak-Lui Wong et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model
- (2012) Y. Jeffrey Wu et al. JOURNAL OF NEURO-ONCOLOGY
- Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
- (2012) D. Yee JNCI-Journal of the National Cancer Institute
- Breast-cancer stem cells—beyond semantics
- (2012) Sunil Badve et al. LANCET ONCOLOGY
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells
- (2012) R. Rao et al. MOLECULAR CANCER THERAPEUTICS
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population
- (2012) Hasan Korkaya et al. MOLECULAR CELL
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Epigenetic Readers in Cancer
- (2012) Mark A. Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients
- (2012) C. Bartholomeusz et al. ONCOLOGIST
- Hedgehog Signaling in Tumor Cells Facilitates Osteoblast-Enhanced Osteolytic Metastases
- (2012) Shamik Das et al. PLoS One
- Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype
- (2012) Wen-Huan Xu et al. PLoS One
- Intratumor Heterogeneity: Seeing the Wood for the Trees
- (2012) T. A. Yap et al. Science Translational Medicine
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
- (2011) M. N. Fornier et al. ANNALS OF ONCOLOGY
- Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
- (2011) M. Campone et al. ANNALS OF ONCOLOGY
- The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin
- (2011) Osvaldo Pontiggia et al. BREAST CANCER RESEARCH AND TREATMENT
- The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer
- (2011) Ji-Yu Li et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
- (2011) K Pandya et al. BRITISH JOURNAL OF CANCER
- Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells
- (2011) Ubaldo E. Martinez-Outschoorn et al. CANCER BIOLOGY & THERAPY
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells
- (2011) Nilay Sethi et al. CANCER CELL
- HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
- (2011) Xiaoping Huang et al. CANCER LETTERS
- Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks
- (2011) Suling Liu et al. CANCER RESEARCH
- LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution
- (2011) H. E. Barker et al. CANCER RESEARCH
- Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer
- (2011) Ayca Gucalp et al. Clinical Breast Cancer
- The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia
- (2011) J. Wang et al. CLINICAL CANCER RESEARCH
- A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer
- (2011) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas
- (2011) Gema Moreno-Bueno et al. EMBO Molecular Medicine
- Breast cancer stem cells, cytokine networks, and the tumor microenvironment
- (2011) Hasan Korkaya et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Insight into the heterogeneity of breast cancer through next-generation sequencing
- (2011) Hege G. Russnes et al. JOURNAL OF CLINICAL INVESTIGATION
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
- (2011) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary Hodgkin's Lymphoma of the Rectum: An Unusual Presentation
- (2011) Alexandre A.B.A. da Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
- (2011) L. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Cancer epigenetics reaches mainstream oncology
- (2011) Manuel Rodríguez-Paredes et al. NATURE MEDICINE
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Harnessing synthetic lethal interactions in anticancer drug discovery
- (2011) Denise A. Chan et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast Cancer Cells Induce Cancer-Associated Fibroblasts to Secrete Hepatocyte Growth Factor to Enhance Breast Tumorigenesis
- (2011) Shiaw-Wei Tyan et al. PLoS One
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
- (2011) C. C.-L. Wong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers
- (2010) Peter Kabos et al. BREAST CANCER RESEARCH AND TREATMENT
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
- (2010) K. A. Edgar et al. CANCER RESEARCH
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Synthetic Lethality through Combined Notch-Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
- (2010) Y. Dong et al. CANCER RESEARCH
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer
- (2010) Lyndsay V. Rhodes et al. CANCER RESEARCH
- Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
- (2010) X. Huang et al. CANCER RESEARCH
- Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
- (2010) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
- (2010) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways
- (2010) Sara Previdi et al. EUROPEAN JOURNAL OF CANCER
- CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model
- (2010) Saima Hassan et al. INTERNATIONAL JOURNAL OF CANCER
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
- (2010) Christophe Ginestier et al. JOURNAL OF CLINICAL INVESTIGATION
- Genetic Testing in Li-Fraumeni Syndrome: Uptake and Psychosocial Consequences
- (2010) Chantal R.M. Lammens et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
- (2010) Anna Maria Calcagno et al. JNCI-Journal of the National Cancer Institute
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
- (2010) Vivian Barry-Hamilton et al. NATURE MEDICINE
- A novel interaction between HER2/neu and cyclin E in breast cancer
- (2010) E A Mittendorf et al. ONCOGENE
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression
- (2009) M Yan et al. BRITISH JOURNAL OF CANCER
- Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche
- (2009) Janine T. Erler et al. CANCER CELL
- Mammary Epithelial-Specific Ablation of the Focal Adhesion Kinase Suppresses Mammary Tumorigenesis by Affecting Mammary Cancer Stem/Progenitor Cells
- (2009) M. Luo et al. CANCER RESEARCH
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
- (2009) O. K. Mirzoeva et al. CANCER RESEARCH
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
- (2009) Emmanuelle Charafe-Jauffret et al. CANCER RESEARCH
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
- (2009) Piyush B. Gupta et al. CELL
- DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency
- (2009) Timothy Hoey et al. Cell Stem Cell
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer
- (2009) Andrew M. Wardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of reactive oxygen species levels and radioresistance in cancer stem cells
- (2009) Maximilian Diehn et al. NATURE
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
- (2009) Pierre Farmer et al. NATURE MEDICINE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
- (2009) M. G. Ponzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways
- (2008) Aisha Siddiqa et al. BMC CANCER
- FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
- (2008) Hazem Ghebeh et al. BMC CANCER
- Timing is everything: Order of administration of 5-aza 2′ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity
- (2008) Christine L. Hostetter et al. CANCER LETTERS
- Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
- (2008) I. Bernard-Pierrot et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
- (2008) P. Rizzo et al. CANCER RESEARCH
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
- (2008) D. Meijer et al. ENDOCRINE-RELATED CANCER
- S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
- (2008) Rachel L. Yamnik et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis
- (2008) Chad J. Creighton et al. JOURNAL OF CLINICAL ONCOLOGY
- A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer
- (2008) Eugene H. Huang et al. JOURNAL OF SURGICAL RESEARCH
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
- (2008) X. Li et al. JNCI-Journal of the National Cancer Institute
- No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas
- (2008) Wen Qiu et al. NATURE GENETICS
- Stromal gene expression predicts clinical outcome in breast cancer
- (2008) Greg Finak et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now